A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups
DOI10.1111/BIOM.12842zbMATH Open1414.62462OpenAlexW2793259039WikidataQ48188540 ScholiaQ48188540MaRDI QIDQ4628384FDOQ4628384
Authors: Thomas A. Murray, Ying Yuan, Peter F. Thall, Joan H. Elizondo, Wayne L. Hofstetter 
Publication date: 13 March 2019
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc6054910
Recommendations
- BAGS: a Bayesian adaptive group sequential trial design with subgroup-specific survival comparisons
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- Optimal adaptive randomized designs for clinical trials
- An adaptive trial design to optimize dose-schedule regimes with delayed outcomes
- Design of Group Sequential Clinical Trials with Ordinal Categorical Data Based on the Mann–Whitney–Wilcoxon Test
Applications of statistics to biology and medical sciences; meta analysis (62P10) Optimal statistical designs (62K05)
Cited In (5)
- A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
- Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups
- TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy
- BAGS: a Bayesian adaptive group sequential trial design with subgroup-specific survival comparisons
- A multi-armed Bayesian ordinal outcome utility-based sequential trial with a pairwise null clustering prior
This page was built for publication: A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4628384)
